{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-035939","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.655781+00:00","generated_at":"2026-06-12T22:17:11.599181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biomea Fusion Q2 2023: positive diabetes & AML data; net loss widens","bullets":["Diabetes: in Cohort 3 (100 mg BMF-219 QD), mean HbA1c reduction of 1.49% at Week 12, 62% greater than at end of 4-week dosing.","60% of Cohort 3 patients achieved HbA1c ≤7% at Week 12 vs 30% at Week 4; no severe TEAEs off treatment.","Oncology: 2 complete responses out of 5 relapsed/refractory AML patients carrying menin-dependent mutations at Dose Level 4.","Cash $223.3M as of June 30, 2023; net loss $24.9M in Q2 2023 vs $17.3M in Q2 2022.","Initiated Phase I for BMF-500 (COVALENT-103), a third-generation covalent FLT3 inhibitor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-035939","json":"https://secwatch.observer/filing/0000950170-23-035939.json","markdown":"https://secwatch.observer/filing/0000950170-23-035939.md","text":"https://secwatch.observer/filing/0000950170-23-035939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023035939/0000950170-23-035939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023035939/bmea-20230731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T22:17:11.599181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55b374e8361be2ec156a3d047eacf93ed7443b71","claim":"Biomea Fusion, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On July 31, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023035939/0000950170-23-035939-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}